By Kailyn Rhone
Oncology-focused biotech company Exelixis said the Food and Drug Administration will review its application to expand the use of its cancer drug, Cabozantinib.
The cancer drug is used to treat adults with advanced pancreatic and extra-pancreatic neuroendocrine tumors.
The FDA set a deadline of April 3 to decide whether to approve the expanded use of Cabozantinib, the company said Tuesday.
Exelixis plans to meet with the FDA's oncologic drugs advisory committee in March to discuss the drug's potential new uses. The meeting will review the safety and effectiveness of the cancer drug Cabozantinib for new uses, though it won't discuss the drug's current approved uses.
The committee will recommend to the commissioner of food and drugs whether the drug should be approved to treat additional cancer types.
Write to Kailyn Rhone at kailyn.rhone@wsj.com
(END) Dow Jones Newswires
11-26-24 1813ET